3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
• 英文别名: 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-6H-pyrazolo[4,3-d]pyrimidin-7-one
• 化学式: C₂₇H₃₄N₈O₆S
• 分子量: 598.683
• InChiKey: MPNWKIDRINJSMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  167
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Methods and compositions for treating diseases and conditions of the eye
  申请人：——

  公开号：US20020119974A1

  公开（公告）日：2002-08-29

  Methods for the prevention and treatment of diseases and conditions of the eye including, but are not limited to: central retinal artery occlusion; central retinal vein occlusion; optic neuropathy including, but not limited to, anterior ischemic optic neuropathy and glaucomatous optic neuropathy; and macular (dry) degeneration are disclosed. These methods comprise administering to a patient a prophylactically or therapeutically effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitor. Pharmaceutical compositions and dosage forms comprising cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.

  披露了预防和治疗眼部疾病和病况的方法，包括但不限于：中央视网膜动脉阻塞；中央视网膜静脉阻塞；视神经病变，包括但不限于前部缺血性视神经病变和青光眼性视神经病变；以及黄斑（干性）变性。这些方法包括向患者投予预防性或治疗性有效量的环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂。还披露了含有环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂的药物组合物和剂型。
• [EN] PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION<br/>[FR] INHIBITEURS DE CGMP PDE5 DE PYRAZOLOPYRIMIDINONE SERVANT A TRAITER LE DYSFONCTIONNEMENT SEXUEL
  申请人：PFIZER INC.

  公开号：WO1999054333A1

  公开（公告）日：1999-10-28

  (EN) Compounds of formulae (IA) and (IB) wherein R1 is C1 to C3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1 to C4 alkoxy; halo; CN; CF3; OCF3 or C1 to C4 alkyl wherein said C1 to C4 alkyl group is optionally substituted by C1 to C4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2 is C1 to C6 alkyl and R13 is OR3 or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).(FR) Composés représentés par les formules (IA) et (IB) : (IA) (IB) dans lesquelles R1 représente alkyle C1 à C3 éventuellement substitué par phényle, Het ou un groupe hétérocyclique à liaison N sélectionné dans pipéridinyle et morpholinyle ; ledit groupe phényle étant éventuellement substitué par un ou plusieurs substituants sélectionnés dans alkoxy C1 à C4 ; CN ; CF3 ; OCF3 ou alkyle C1 à C4, chaque groupe alkyle C1 à C4 étant éventuellement substitué par haloalkyle C1 à C4 ou haloalkoxy, les deux étant substitués par un ou plusieurs atomes de halo ; R2 représente alkyle C1 à C6 et R13 représente OR3 ou NR5R6, ou leurs sels acceptables sur le plan pharmaceutique ou vétérinaire ou les solvates acceptables sur le plan pharmaceutique ou vétérinaire de l'une ou l'autre de ces entités constituant des inhibiteurs puissants et sélectifs de guanosine 3',5'-monophosphate phosphodiestérase cyclique de type 5 (cGMP PDE5) utiles pour traiter, entre autres, le dysfonctionnement érectile masculin (MED) et le dysfonctionnement sexuel féminin (FSD).

  化合物的化学式为(IA)和(IB)，其中R1是C1到C3的烷基，可选地被苯基、Het或选自哌啶基和吗啡啉基的N-连接杂环基团取代；其中所述的苯基可以被一个或多个取代基所取代，所述取代基选自C1到C4的烷氧基、卤素、氰基、三氟甲基、三氟甲氧基或C1到C4的烷基，其中所述的C1到C4的烷基可以被C1到C4的卤代烷基或卤代烷氧基所取代，其中每个取代基都可以被一个或多个卤素原子所取代；R2是C1到C6的烷基，R13是OR3或NR5R6，或其在药学或兽医学上可接受的盐，或者是任一实体在药学或兽医学上可接受的溶剂，它们是5型环鸟苷酸3'，5'-单磷酸磷酸二酯酶（cGMP PDE5）的有效和选择性抑制剂，并可用于治疗男性勃起功能障碍（MED）和女性性功能障碍（FSD）等疾病。
• Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
  申请人：——

  公开号：US20010039271A1

  公开（公告）日：2001-11-08

  Compounds of the formulae (IA) and (IB): 1 wherein R 1 is C 1 to C 3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C 1 to C 4 alkoxy; halo; CN; CF 3 ; OCF 3 or C 1 to C 4 alkyl wherein said C 1 to C 4 alkyl group is optionally substituted by C 1 to C 4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R 2 is C 1 to C 6 alkyl and R 13 is OR 3 or NR 5 R 6 , or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

  式(I-A)和(I-B)的化合物：其中，R1是C1到C3烷基，可选地被苯基，Het或选择自哌啶基和吗啉基的N-连接杂环基团取代；其中，所述苯基可选地被一个或多个取代基所取代，所述取代基选择自C1到C4烷氧基，卤素，CN，CF3，O 或C1到C4烷基，其中所述C1到C4烷基可选地被C1到C4卤代烷基或卤代烷氧基所取代，所述卤代烷基或卤代烷氧基中的任意一个被一个或多个卤素原子所取代；R2是C1到C6烷基，R13是OR3或NR5R6，或其药学上或兽医学上可接受的盐，或者是上述任一实体的药学上或兽医学上可接受的溶剂，它们是选择性抑制剂5型环鸟苷酸3′，5′-单磷酸磷酸二酯酶（cGMP PDE5）的有效药物，并且在治疗男性勃起功能障碍（MED）和女性性功能障碍（FSD）等方面具有用途。
• Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator
  申请人：Pfizer Products Inc.

  公开号：EP1090644A2

  公开（公告）日：2001-04-11

  This invention relates to the treatment of erectile dysfunction with a combination of (1) a compound selected from potassium channel openers, and (2) a compound selected from compounds which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compositions and kits comprising such impotence treating compounds.

  本发明涉及(1)选自钾通道开放剂的化合物和(2)选自可提高 cGMP 水平的化合物的组合治疗勃起功能障碍。首选西地那非或其药学上可接受的盐作为 cGMP PDE 升高剂。此外，还包括含有此类阳痿治疗化合物的组合物和试剂盒。
• Pyridine-3-carboxylic acid derivatives and their use as intermediates
  申请人：PFIZER INC.

  公开号：EP1371647A2

  公开（公告）日：2003-12-17

  The present invention relates to compounds of the formula (X) which are useful in the synthesis of pyrazolopyrimidinone compounds: wherein: R13 is C1 to C4 alkyl optionally substituted with one or two substituents selected from OH, C1 to C4 alkoxy, benzyloxy, NR5R6, phenyl, furanyl and pyridinyl; C3 to C6 cycloalkyl; 1-(C1 to C4 alkyl)piperidinyl; tetrahydrofuranyl or tetrahydropyranyl; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl, or, together with the nitrogen atom to which they are attached, form a pyrrolidinyl, piperidinyl or morpholinyl group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10 piperazinyl group optionally substituted with one or two C1 to C4 alkyl groups and optionally in the form of its 4-N-oxide; R10 is H; C1 to C4 alkyl optionally substituted with one or two substituents selected from OH, NR5R6, CONR5R6, phenyl optionally substituted with C1 to C4 alkoxy, benzodioxolyl and benzodioxanyl; C3 to C6 alkenyl; pyridinyl or pyrimidinyl; or a salt of such compound, or an acid chloride derivative of such compound.

  本发明涉及式（X）化合物，该化合物可用于合成吡唑嘧啶酮化合物： 其中 R13 是任选被一个或两个取代基取代的 C1 至 C4 烷基，这些取代基选自 OH、C1 至 C4 烷氧基、苄氧基、NR5R6、苯基、呋喃基和吡啶基；C3 至 C6 环烷基；1-(C1 至 C4 烷基)哌啶基；四氢呋喃基或四氢吡喃基； R4 是 SO2NR7R8； R5 和 R6 各自独立地选自 H 和 C1 至 C4 烷基，或与它们连接的氮原子一起形成吡咯烷基、哌啶基或吗啉基； R7 和 R8 与它们所连接的氮原子一起形成 4-R10 哌嗪基团，该基团可选择被一个或两个 C1 至 C4 烷基取代，也可选择以其 4-N-oxide 的形式存在； R10 是 H；任选被一个或两个取代基取代的 C1 至 C4 烷基，这些取代基选自 OH、NR5R6、CONR5R6、任选被 C1 至 C4 烷氧基取代的苯基、苯并二噁茂基和苯并二噁烷基；C3 至 C6 烯基；吡啶基或嘧啶基； 或此类化合物的盐，或此类化合物的酸性氯化物衍生物。